Siemens Molecular Imaging Draws on Innovation to Transform Patient Care.

CHICAGO -- Driving innovation in molecular imaging, Siemens Medical Solutions introduces a three-tiered strategy to transform the detection and treatment of disease. At the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 2 (booth #4337) in Chicago, Siemens will highlight its solutions and vision for taking healthcare to the molecular level, including clinical and preclinical molecular imaging solutions, and biomarker development.

"We are moving from treating the illness to treating the patient, utilizing tools from leading-edge hybrid scanners that detect abnormalities before symptoms appear to new biomarkers for identifying disease pathways," said Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. "Innovation is in our genes, both from a historical perspective at Siemens and looking into what our future holds for healthcare. We at Siemens are leading the way and putting molecular medicine into practice."

Following the company's acquisition of CTI Molecular Imaging, Inc., earlier this year and the creation of the Siemens' Molecular Imaging Division, Siemens is revolutionizing disease diagnosis at the molecular level to ultimately improve patient care. The Division is influencing the complete healthcare continuum with an array of molecular medicine solutions, with concentrations in the following areas:

--Hybrid Imaging Solutions - Siemens hybrid offerings are already influencing how patients are diagnosed and treated. For example, Positron Emission Tomography/Computed Tomography (PET/CT) scanners combine the anatomical imaging supplied by CT with the confirmation of increased molecular and cellular activity from PET. One of the hybrid systems being highlighted at RSNA will be the Biograph(TM) 64 PET/CT system, providing unprecedented image quality with its ability to perform high-resolution CT angiography and myocardial perfusion, viability, and function in one accurately registered exam. Also being featured at RSNA is the Symbia(R) TruePoint(TM) Single-Photon Emission Computed Tomography (SPECT--CT), which combines the functional sensitivity of SPECT with the anatomical detail of diagnostic multislice CT. With a single scanning session, this imaging technology quickly captures comprehensive, accurate information on both the molecular and anatomical levels, enabling clinicians to detect changes in molecular activity even before structural changes become visible.

--Advanced Clinical Applications - Siemens' expertise in clinical applications will be highlighted with syngo(R) TrueD, an advanced visualization tool that enables physicians to compare patient scans from two different points in time, such as pre- and post- therapy. Scenium advances neurological evaluation by enabling automatic correlation of the patient study with an average brain for assessment of abnormalities.

--Preclinical Imaging - Siemens offers the latest in vivo preclinical imaging technologies to facilitate basic research as well as support for drug development processes. Evaluating new treatments and visualizing different types of cancers enables researchers to detect disease earlier and treat it more effectively. Solutions such as microPET(R), microCAT(R) and microCAT+SPECT scanners offer early insight into in vivo pharmacokinetics and pharmacodynamics, providing the bridge between the laboratory and the clinic.

--Biomarkers - Siemens is facilitating the development of new molecular imaging biomarkers that enable the biological mechanisms of disease to be identified and understood. Results may help physicians determine personalized therapies for patients by pinpointing the active pathways in the disease progression.

"Because of innovations in molecular imaging technologies and the increasingly important role of molecular imaging in disease detection, we are seeing fundamental changes in what we can detect and learn about diseases," said Reitermann. "However, gathering better information is just the first step. Siemens and its partners are pioneering the development of disease specific tracers and innovative clinical and preclinical imaging solutions that will enable diagnosis and treatment of disease to be predictive, personalized and ultimately preventive."

Siemens Medical Solutions of Siemens AG (NYSE:SI) with headquarters in Malvern, Pennsylvania and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and group profit of 976 million EUR for fiscal 2005 (preliminary figures). More information can be obtained by visiting http://www.usa.siemens.com/medical-pressroom.